Medical information Clinical review pending

Genetic Testing

ALG6 Gene Glycosylation Disorder Type 1C Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the ALG6 gene, associated with Glycosylation Disorder Type 1C and neurological conditions. Recommended for individuals with relevant symptoms or family history.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results: Confirm with the laboratory before booking.
Preparation: A clinical history of the patient is required. A genetic counseling session, including a pedigree chart of affected family members, is recommended before testing.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ALG6 Gene Glycosylation Disorder Type 1C Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Individuals with symptoms suggestive of Glycosylation Disorder Type 1C (e.g., developmental delays, seizures).
✓Individuals with a family history of Glycosylation Disorder Type 1C or related neurological conditions.
✓Genetic counseling for individuals considering family planning with a known risk.
✓Confirmation of diagnosis in suspected cases.
✓Understanding the genetic basis of neurological symptoms.

In plain language

What this test helps you understand

This test helps identify specific mutations in the ALG6 gene responsible for Glycosylation Disorder Type 1C. Detecting these mutations can aid in diagnosing the condition, understanding its genetic basis, and informing management strategies for affected individuals.

The ALG6 Gene Glycosylation Disorder Type 1C NGS Genetic DNA Test is a diagnostic tool using Next Generation Sequencing (NGS) technology. It identifies mutations in the ALG6 gene, which are linked to Glycosylation Disorder Type 1C, a condition that can cause significant neurological complications. Early detection through this genetic test can help in managing symptoms and understanding potential risks. This test analyzes a DNA sample to determine if an individual carries mutations associated with these disorders. It is particularly relevant for those with a family history of glycosylation disorders or neurological conditions, or individuals presenting with symptoms like developmental delays or seizures. Genetic counseling is recommended to understand the implications of the test results and discuss family planning.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationA clinical history of the patient is required. A genetic counseling session, including a pedigree chart of affected family members, is recommended before testing.

SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.

MethodologyNext Generation Sequencing (NGS) of the ALG6 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test detects mutations within the ALG6 gene. It may not detect all possible mutations, such as deep intronic mutations or large deletions/duplications, unless specifically requested. A negative result does not completely rule out a genetic cause for the symptoms. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Glycosylation Disorder Type 1C is a genetic condition caused by mutations in the ALG6 gene. It affects the body's ability to properly attach sugar molecules (glycosylation) to proteins, which can lead to various health problems, particularly neurological issues.

Testing is recommended for individuals showing symptoms like developmental delays or seizures, or those with a family history of Glycosylation Disorder Type 1C or similar neurological conditions.

A blood sample, extracted DNA, or a single drop of blood on an FTA card can be used for this test.

Confirm with the laboratory before booking.

The test identifies if you carry specific mutations in the ALG6 gene. A genetic counselor or doctor can help interpret the results in the context of your health and family history to understand potential risks.

Yes, genetic counseling is highly recommended before and after testing to understand the test's implications, interpret results, and discuss family planning options.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp